Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study

Y. Benavente, G. Mbisa, N. Labo, D. Casabonne, N. Becker, M. Maynadie, L. Foretova, P. L. Cocco, A. Nieters, A. Staines, P. Bofetta, P. Brennan, D. Whitby, S. De Sanjosé

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Background: Kaposi's sarcoma-associated herpes virus is associated with primary effusion lymphoma and multicentric Castleman's disease.Methods: Seropositivity to lytic and latent Kaposi's sarcoma herpes virus (KSHV) antigens were examined in 2083 lymphomas and 2013 controls from six European countries. Results: Antibodies against KSHV latent and lytic antigens were detectable in 4.5% and 3.4% of controls, respectively, and 3.6% of cases (P0.05). The KSHV seropositivity was associated with splenic marginal zone lymphoma (SMZL) (odds ratio (OR)4.11, 95% confidence interval (CI)1.57-10.83) and multiple myeloma (OR0.31, 95% CI0.11-0.85).Conclusion:The KSHV is unlikely to contribute importantly to lymphomagenesis among immunocompetent subjects. However, the observed association with SMZL may underline a chronic antigen mechanism in its aetiology.

Original languageEnglish
Pages (from-to)1768-1771
Number of pages4
JournalBritish Journal of Cancer
Volume105
Issue number11
DOIs
StatePublished - 22 Nov 2011

Keywords

  • Kaposi's sarcoma-associated herpes virus
  • epidemiology
  • human herpes virus 8
  • lymphoma
  • serology

Fingerprint

Dive into the research topics of 'Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study'. Together they form a unique fingerprint.

Cite this